Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13055682 | 0.80 | LMNA (0.52) | LMNAHSD17B10PTPN1 | |
| SCHEMBL2803375 | 0.77 | LMNA (0.53) | LMNAHSD17B10PTPN1 | |
| SCHEMBL2804681 | 0.77 | LMNA (0.53) | LMNAHSD17B10PTPN1 | |
| SCHEMBL2499788 | 0.75 | LMNA (0.52) | LMNAHSD17B10PTPN1 | |
| SCHEMBL13311937 | 0.72 | LMNA (0.53) | LMNAHSD17B10PTPN1 | |
| SCHEMBL2650564 | 0.69 | POLB (0.31) | LMNA | |
| SCHEMBL46361 | 0.67 | KMT2A (0.34) | LMNA | |
| SCHEMBL785938 | 0.66 | POLB (0.33) | — | |
| Water SCHEMBL31387323 | 0.65 | ALDH1A1 (0.33) | LMNA | |
| SCHEMBL17147797 | 0.65 | KDM4E (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298368-A1 | ANTAGONISTS OF PGD2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298368-A1 | ANTAGONISTS OF PGD2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298368-A1 | ANTAGONISTS OF PGD2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| WO-2009061681-A2 | ANTAGONISTS OF PGD2 RECEPTORS | AMIRA PHARMACEUTICALS, INC (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298368-A1 | ANTAGONISTS OF PGD2 RECEPTORS | PTGDR2, PTGDR, LTB4R2 | LMNA 4192/4885HSD17B10 1217/4885PTPN1 2709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.